Effect of ibuprofen on cyclooxygenase and nitric oxide synthase of gastric mucosa: Correlation with endoscopic Lesions and Adverse Reactions

Digestive Diseases and Sciences

Volumn 49, Issue 9, 2004, Pages 1538-1544

  Gallego Sandín, Sonia ^a   Novalbos, Jesús ^a   Rosado, Aránzazu ^a   Gisbert, Javier P ^a   Gálvez Múgica, María Ángeles ^a   García, Antonio G ^a   Pajares, José María ^a   Abad Santos, Francisco ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

anti inflammatory agents; cyclooxygenase; gastric mucosa; ibuprofen; nitric oxide synthase; nonsteroidal

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; IBUPROFEN; IBUPROFEN DERIVATIVE; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIGESTIVE SYSTEM INJURY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL ENDOSCOPE; HELICOBACTER PYLORI; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH MUCOSA; STOMACH PROTECTION; WESTERN BLOTTING;

ADOLESCENT; ADULT; BIOPSY, NEEDLE; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTRIC MUCOSA; GASTROSCOPY; HUMANS; IBUPROFEN; IMMUNOHISTOCHEMISTRY; MALE; NITRIC OXIDE SYNTHASE; PROBABILITY; PROSPECTIVE STUDIES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; REFERENCE VALUES; RISK FACTORS; SINGLE-BLIND METHOD; THROMBOXANES;

EID: 4644364924     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DDAS.0000042261.22387.06     Document Type: Article

References (39)

1. Henry D, Lim LL, Garcia Rodriguez LA, et al.: Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis. BMJ 312:1563-1566, 1996
2. Halter F, Tarnawski AS, Schmassmann A, Peskar BM: Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: Controversial issues and perspectives. Gut 49:443-453, 2001
3. Elliott SN, McKnight W, Cirino G, Wallace JL: A nitric oxide-releasing nonsteroideal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology 109:524-530, 1995
4. Fiorucci S, Santucci L, Gresele P, Faccino RM, Del Soldato P, Morelli A: Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: A proof of concept endoscopic study. Gastroenterology 124:600-607, 2003
5. Valdivier RW, Eidsath A, Banks SM, et al.: Down-regulation of nitric oxide production by ibuprofen in human volunteers. J Pharmacol Exp Ther 289:1398-1403, 1999
6. Tanaka A, Kunikata T, Mizoguchi H, Kato S, Takeuchi K: Dual action of nitric oxide in pathogenesis of indomethacin-induced small intestinal ulceration in rats. J Physiol Pharmacol 50:405-417, 1999
7. Fischer H, Becker JC, Boknik P, et al.: Expression of endothelial cell-derived nitric oxide synthase (eNOS) is increased during gastric adaptation to chronic aspirin intake in humans. Aliment Pharmacol Ther 13:507-514, 1999
8. Gisbert JP, Abad-Santos F, Novalbos J, et al.: Comparison of gastric endoscopic lesions and tolerability to ibuprofen and ibuprofen-arginate in healthy subjects. Eur J Gastroenterol Hepatol, 2004 (in press)
9. Hawkey CJ, Hawthorne AB, Hudson N, Cole AT, Mahida YR, Daneshmend TK: Separation of the impairment of haemostasis by aspirin from mucosal injury in the human stomach. Clin Sci (Lond) 81:565-573, 1991
10. Lanza FL, Rack MF, Simon TJ, et al.: Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 13:761-767, 1999
11. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685, 1970
12. Kim TI, Lee YC, Lee KH, et al.: Effects of nonsteroidal anti-inflammatory drugs on Helicobacter pylori-infected gastric mucosae of mice: Apoptosis, cell proliferation, and inflammatory activity. Infect Immun 69:5056-5063, 2001
13. Tanaka A, Araki H, Komoike Y Hase S, Takeuchi K: Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs. J Physiol Paris 95:21-27, 2001
14. Donnelly MT, Richardson P, Hawkey CJ, Courtauld E, Stack WA: Dose-dependent effects of ketoprofen on the human gastric mucosa in comparison with ibuprofen. Aliment Pharmacol Ther 14:543-549, 2000
15. Zarrilli R, Tuccillo C, Santangelo M, Nardone G, Romano M: Increased COX-2, but not COX-1, mRNA expression in Helicobacter pylori gastritis. Am J Gastroenterol 94:3376-3378, 1999
16. Tatsuguchi A, Sakamoto C, Wada K, et al.: Localisation of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans. Gut 46:782-789, 2000
17. Fu S, Ramanujam KS, Wong A, et al.: Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology 116:1319-1329, 1999
18. Mizuno H, Sakamoto C, Matsuda K, et al.: Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 112:387-397, 1997
19. Chan FK, To KF, Ng YP, et al.: Expression and cellular localization of COX-1 and -2 in Helicobacter pylori gastritis. Aliment Pharmacol Ther 15:187-193, 2001
20. Fischer H, Huber V, Boknik P, et al.: Effect of Helicobacter pylori eradication on cyclooxigenase 2 (COX-2) and inducible nitric oxide synthase (iNOS) expression during gastric adaptation to aspirin (ASA) in humans. Microsc Res Tech 53:336-342, 2001
21. Jackson LM, Wu KC, Mahida YR, Jenkins D, Hawkey CJ: Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut 47:762-770, 2000
22. Konturek PC, Rembiasz K, Konturek SJ, et al.: Gene expression of ornithine decarboxylase, cyclooxygenase-2, and gastrin in atrophic gastric mucosa infected with Helicobacter pylori before and after eradication therapy. Dig Dis Sci 48:36-46, 2003
23. Wallace JL, McKnight W, Reuter BK, Vergnolle N: NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119:706-714, 2000
24. Li CQ, Pignatelli B, Ohshima H: Coexpresion of interleukin-8 and inducible nitric oxide synthasa in gastric mucosa infected with cagA+ Helicobacter pylori. Dig Dis Sci 45:55-62, 2000
25. Felley CP, Pignatelli B, Van Melle GD, et al.: Oxidative stress in gastric mucosa of asymptomatic humans infected with Helicobacter pylori: Effect of bacterial eradication. Helicobacter 7:342-348, 2002
26. Kaise M, Miwa J, Iihara K, Suzuki N, Oda Y, Ohta Y: Helicobacter pylori stimulates inducible nitric oxide synthase in diverse topographical patterns in various gastroduodenal disorders. Dig Dis Sci 48:636-643, 2003
27. Bertrand V, Guimbaud R, Sogni P, et al.: Role of tumour necrosis factor-alpha and inducible nitric oxide synthase in the prevention of nitro-flurbiprofen small intestine toxicity. Eur J Pharmacol 356:245-253, 1998
28. Cirino G: Nitric oxide releasing drugs: From bench to bedside. Dig Liver Dis 35 (Suppl 2):S2-S8, 2003
29. Cho CH: Current roles of nitric oxide in gastrointestinal disorders. J Physiol Paris 95:253-256, 2001
30. Martin MJ, Jiménez MD, Motilva V: New issues about nitric oxide and its effects on the gastrointestinal tract. Curr Pharm Des 7:881-908, 2001
31. Friedman H, Seckman C, Lanza F, Royer G, Perry K, Francom S: Clinical pharmacology of predisintegrated ibuprofen 800 mg tablets: an endoscopic and pharmacokinetic study. J Clin Pharmacol 30:57-63, 1990
32. Black P, Max MB, Desjardins P, Norwood T, Ardia A, Pallota T: A randomized, double-blind, placebo-controlled comparison af the analgesic efficacy, onset of action, and tolerability of ibuprofen arginate and ibuprofen in postoperative dental pain. Clin Ther 24:1072-1089, 2002
33. Desjardins P, Black P, Papageorge M, et al.: Ibuprofen arginate provides effective relief from postoperative dental pain with a more rapid onset of action than ibuprofen. Eur J Clin Pharmacol 58:387-394, 2002
34. Mehlisch DR, Ardia A, Pallotta T: A controlled comparative study of ibuprofen arginate versus conventional ibuprofen in the treatment of postoperative dental pain. J Clin Pharmacol 42:904-911, 2002
35. Martín Calero MJ, Jiménez MD, Alarcón de la Lastra C, et al.: Protective effect of L-arginine against ibuprofen-induced gastric injury in rats. Pharmaceutical Sciences 3:609-612, 1997
36. Brzozowski T, Konturek SJ, Sliwowski Z, Drozdowicz D, Zaczek M, Kedra D: Role of L-arginine, a substrate for nitric oxide-synthase, in gastroprotection and ulcer healing. J Gastroenterol 32:442-452, 1997
37. Brzozowski T, Konturek SJ, Drozdowicz D, Dembinski A, Stachura J: Healing of chronic gastric ulcerations by L-arginine. Role of nitric oxide, prostaglandins, gastrin and polyamines. Digestion 56:463-471, 1995
38. Jiménez D, Martin MJ, Pozo D, et al.: Mechanisms involved in protection afforded by L-arginine in ibuprofen-induced gastric damage: Role of nitric oxide and prostaglandins. Dig Dis Sci 47:44-53, 2002
39. Santucci L, Fiorucci S, Patoia L, di Matteo FM, Brunori PM, Morelli A: Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated with Helicobacter pylori infection and high levels of pepsinogens. Dig Dis Sci 40:2074-2080, 1995